← Leaderboards
David A Fruman
University Of California Irvine
$9,763,991
Attributed
$10,952,937
Total exposure
12
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,952,937 · 12
By mechanism
T32$3,865,654 · 1
R01$3,146,804 · 2
R21$2,059,925 · 5
DP7$1,636,268 · 1
R03$143,209 · 1
P30$97,536 · 1
Top collaborators
- Aimee L Edinger5 shared
- Marina Y Konopleva2 shared
Most similar at University Of California Irvine
Same institution · by research overlap
- Hung Y Fan$12,341,490
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsTraining ProgramsCollaborationsMalignant NeoplasmsSignal TransductionCancer CellLeadLaboratoriesReportingInhibitor/AntagonistResponseBaseProgramsResistanceInnovationInterestPathway InteractionsIn VitroSignal PathwayFundingLeukemiaPhosphotransferasesIn VivoClinical Trials
Grant awards (46)
A Training Program for Interdisciplinary Cancer Research$333,547
T32 · FY2025 · CA · contact PI
A Training Program for Interdisciplinary Cancer Research$420,050
T32 · FY2024 · CA · contact PI
A Training Program for Interdisciplinary Cancer Research$417,865
T32 · FY2023 · CA · contact PI
A Training Program for Interdisciplinary Cancer Research$354,454
T32 · FY2022 · CA · contact PI
A Training Program for Interdisciplinary Cancer Research$393,312
T32 · FY2021 · CA · contact PI
Systems, Pathways and Targets Program (SPT)$21,845
P30 · FY2020 · CA · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$433,196
T32 · FY2019 · CA · contact PI
Systems, Pathways and Targets Program (SPT)$21,847
P30 · FY2019 · CA · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$379,994
T32 · FY2018 · CA · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$309,382
DP7 · FY2018 · OD · contact PI
Systems, Pathways and Targets Program (SPT)$21,846
P30 · FY2018 · CA · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$10,313
DP7 · FY2018 · OD · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$384,053
T32 · FY2017 · CA · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$317,907
DP7 · FY2017 · OD · contact PI
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer$197,737
R21 · FY2017 · CA · contact PI
Regulation of B cell differentiation by eIF4E$183,705
R21 · FY2017 · AI · contact PI
Systems, Pathways and Targets Program (SPT)$12,548
P30 · FY2017 · CA · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$5,420
T32 · FY2017 · CA · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$355,480
T32 · FY2016 · CA · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$326,472
DP7 · FY2016 · OD · contact PI
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance$308,903
R01 · FY2016 · CA · contact PI
Regulation of B cell differentiation by eIF4E$222,886
R21 · FY2016 · AI · contact PI
Combination strategies to enhance therapy for Ph-like B-ALL$201,951
R21 · FY2016 · HD · contact PI
Repurposing statins to enhance efficacy of BCL-2 antagonists in blood cancer$178,474
R21 · FY2016 · CA · contact PI
Systems, Pathways and Targets Program (SPT)$19,450
P30 · FY2016 · CA · contact PI
A Training Program in Cancer Biology and Therapeutics (CBT)$388,283
T32 · FY2015 · CA · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$331,972
DP7 · FY2015 · OD · contact PI
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance$310,338
R01 · FY2015 · CA · contact PI
Combination strategies to enhance therapy for Ph-like B-ALL$256,714
R21 · FY2015 · HD · contact PI
UCI-GPS: UC Irvine Graduate Professional Success$340,222
DP7 · FY2014 · OD · contact PI
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance$301,785
R01 · FY2014 · CA · contact PI
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance$292,629
R01 · FY2013 · CA · contact PI
Solving the elusive mechanism of rapamycin action in lymphocytes$217,199
R21 · FY2013 · AI · contact PI
TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance$324,025
R01 · FY2012 · CA · contact PI
Solving the elusive mechanism of rapamycin action in lymphocytes$191,927
R21 · FY2012 · AI · contact PI
Immunoregulatory effects of novel mTOR inhibitors$71,245
R03 · FY2011 · AI · contact PI
Immunoregulatory effects of novel mTOR inhibitors$71,964
R03 · FY2010 · AI · contact PI
LIVE CELL IMAGING OF CD4+ T-CELL CHEMOKINESIS OVER IMMOBILIZED CCL21$3,541
P41 · FY2008 · RR · contact PI
Phosphoinositide 3-Kinase Function in Lymphocytes$237,893
R01 · FY2006 · AI · contact PI
Phosphoinositide 3-Kinase Function in Lymphocytes$342,860
R01 · FY2005 · AI
PI3K Signaling in Single Lymphocytes Analyzed by LMS$223,974
R21 · FY2005 · AI
Phosphoinositide 3-Kinase Function in Lymphocytes$342,185
R01 · FY2004 · AI
PI3K Signaling in Single Lymphocytes Analyzed by LMS$185,358
R21 · FY2004 · AI
Phosphoinositide 3-Kinase Function in Lymphocytes$343,452
R01 · FY2003 · AI
Phosphoinositide 3-Kinase Function in Lymphocytes$320,404
R01 · FY2002 · AI
Phosphoinositide 3-Kinase Function in Lymphocytes$22,330
R01 · FY2002 · AI